Free shipping on all orders over $ 500

Rucaparib Camsylate

Cat. No. M5851

All AbMole products are for research use only, cannot be used for human consumption.

Rucaparib Camsylate Structure
Size Price Availability Quantity
5mg USD 65  USD65 In stock
10mg USD 115  USD115 In stock
50mg USD 270  USD270 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Rucaparib significantly potentiated TMZ-induced tumor regrowth delay in a flank tumor model of GBM12. Median time for tumor to exceed a 1000 mm3 size endpoint for placebo, TMZ, and TMZ/rucaparib treatment was 32, 86, and 121 days, p < 0.01, respectively. In contrast, the addition of rucaparib to TMZ therapy in GBM12 orthotopic xenografts was ineffective (median survival: placebo 16 days, TMZ 68 days and TMZ/rucaparib 81 days, p = 0.88. Therefore, subsequent studies focused on evaluating whether exclusion of rucaparib from the brain and orthotopic brain tumors might contribute to the lack of efficacy observed in the orthotopic xenograft models.

Protocol (for reference only)
Cell Experiment
Cell lines GBM12 cell
Preparation method Cells were incubated with 2 −M rucaparib for 60 minutes at 37°C and then transport was quenched with cold PBS prior to lysis in 1% Triton X-100. Cell pellets were stored at −80°C until analysis using high-performance liquid chromatography followed by tandem mass spectrometry (LC-MS/MS).
Concentrations 2 μM
Incubation time 24 h
Animal Experiment
Animal models Mice with established intracranial xenografts
Formulation dissolved in dimethylsulfoxide and diluted in saline
Dosages 1 mg/kg
Administration i.v.
Chemical Information
Molecular Weight 555.67
Formula C10H16O4S.C19H18FN3O
CAS Number 1859053-21-6
Form Solid
Solubility (25°C) 10 mM in DMSO
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Jenner ZB, et al. Future Oncol. Evaluation of rucaparib and companion diagnostics in the PARP inhibitor landscape for recurrent ovarian cancer therapy.

[2] Parrish KE, et al. Mol Cancer Ther. Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System.

Related PARP Products
2-Methylquinazolin-4-ol

2-Methylquinazolin-4-ol is a potent competitive poly(ADP-ribose) synthetase inhibitor, with a Ki of 1.1 μM. 2-Methylquinazolin-4-ol mammalian aspartate transcarbamylase (ATCase) inhibitor, with IC50 of 0.20 mM.

DPQ 

DPQ is a potent PARP-1 inhibitor.

OUL232 

OUL232 is a potent inhibitor of mono-ARTs PARP7, PARP10, PARP11, PARP12, PARP14, and PARP15.

AZ3391 

AZ3391 is a potent inhibitor of PARP.

PARP1-IN-5 

PARP1-IN-5 is a low toxicity, orally active, potent and selective PARP-1 inhibitor (IC50 =14.7 nM).

  Catalog
Abmole Inhibitor Catalog




Keywords: Rucaparib Camsylate supplier, PARP, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.